Boston Scientific Corporation $BSX Stock: O Brien Greene & Co. Inc Lowers Position

O Brien Greene & Co. Inc trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 93.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,820 shares of the medical equipment provider’s stock after selling 92,758 shares during the period. O Brien Greene & Co. Inc’s holdings in Boston Scientific were worth $298,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Boston Scientific during the 1st quarter worth approximately $28,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Boston Scientific in the 1st quarter valued at $32,000. Measured Wealth Private Client Group LLC lifted its stake in shares of Boston Scientific by 244.9% in the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 387 shares during the period. Kelleher Financial Advisors purchased a new stake in Boston Scientific during the second quarter worth $25,000. Finally, Nvwm LLC boosted its holdings in Boston Scientific by 526.2% during the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 542 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BSX shares. Truist Financial lowered their target price on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. Wells Fargo & Company cut their price target on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. Robert W. Baird upped their price target on Boston Scientific from $50.00 to $51.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Citigroup reduced their price target on Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, October 29th. Finally, Evercore lowered their price target on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Stock Performance

NYSE BSX opened at $44.67 on Wednesday. The company has a market cap of $64.74 billion, a PE ratio of 18.93, a price-to-earnings-growth ratio of 1.30 and a beta of 0.60. The stock’s 50 day simple moving average is $44.19 and its 200-day simple moving average is $55.23. Boston Scientific Corporation has a 1-year low of $39.57 and a 1-year high of $105.65. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the previous year, the business earned $0.75 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.